Neurocrine is paying $145,000 per patient for a drug that works

Neurocrine is paying $145,000 per patient for a drug that works. Whether that is a scandal or a solved problem depends on who you ask.

Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics on Monday, gaining access to Vykat XR — the first and only approved drug for hyperphagia in Prader-Willi syndrome, a rare genetic disorder that causes relentless, uncontrollable hunger. The math that matters: Soleno generated roughly $190 million in revenue over about nine months after its March 2025 approval, against an estimated 20,000 diagnosed patients in the United States. That implies an annual cost per patient well north of $100,000 — and a company being acquired at a valuation that only makes sense if the healthcare system quietly absorbs the price.

The deal is a window into how rare disease pricing works in practice. Vykat XR has no competition. Prader-Willi patients need it. Their families cannot wait. Neurocrine is betting that payers will pay, and the BMO analyst projection of $450 million in 2026 sales and $2 billion globally by the mid-2030s suggests the market agrees. The alternative — a patient going without — is not a tolerable option for a drug that controls the defining, dangerous symptom of a lifelong genetic condition.

That is also the uncomfortable part. The same logic that makes rare disease therapeutics commercially attractive — small patient populations, no alternatives, lifetime treatment courses — is the logic that produces six-figure annual costs per patient. The $2.9 billion price tag is not abstract. It is a bet that the healthcare system will treat 20,000 people at whatever price the company sets.

BMO analyst Evan Seigerman called the deal a more sensible path into metabolic disease than Neurocrine's own preclinical obesity candidates, given competitive and regulatory hurdles. That framing is accurate: Vykat XR is approved, selling, and has no direct competitors. The hard question the deal does not answer is what happens to the families who hit insurance limits, prior authorization walls, or outright denials when the list price lands on their annual benefit cap.

Neurocrine is acquiring Soleno at $53 per share — a 34% premium — and expects the deal to close within 90 days, funded with cash on hand. The per-patient math will look different in the earnings reports. What matters for the patients is whether the drug is accessible at the price the market is about to discover.